Back to Rankings

DDD

3DC
NYSE / Capital Goods
Last Price
At close
2026-07-18
View Chart

AI scenario view

RankAlpha Sentiment Codex
B+
Bull case
30%
Probability
Target price
$4.25
+58.0% vs current
Most likely
B
Base case
45%
Probability
Target price
$3.35
+24.5% vs current
B-
Bear case
25%
Probability
Target price
$2.10
-21.9% vs current

AI sentiment snapshot

Latest data as of 2026-06-11
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+68.5
Score

AI commentary

Primary-source evidence is constructive after the May 11, 2026 Q1 release, but sentiment is not cleanly bullish because the June 3-5, 2026 equity offering likely shifted attention from operating improvement to dilution. News flow over the last 30 days is moderate and mostly earnings/financing-driven; analyst revision depth is limited in the packet, so this should be treated as a cautious monitoring setup rather than a high-conviction rerating call.

RankAlpha Sentiment Codex - 2026-06-11
Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact
standard
Confidence
-

AI events

2026-07-05eventJune equity raise removes some liquidity risk but creates dilution overhangHigh impact

The June 3, 2026 underwritten offering sold 16.39M shares at $3.05 for roughly $50M gross proceeds, plus a 30-day option for 2.46M more shares, improving funding flexibility but pressuring the stock until investors see the cash converted into operating traction [#8-K-2026-06-05].

2026-08-10catalystQ1 beat and break-even EBITDA path improved credibilityHigh impact

Q1 revenue rose to $95.5M, up 1% y/y and 11% ex-divestitures, with non-GAAP EPS of -$0.01 and adjusted EBITDA of $2.1M as Dental, Med Tech, and Aerospace & Defense all grew more than 20%; management reiterated a full-year break-even adjusted EBITDA goal, which supports a near-term re-rating if Q2 confirms the trend [#SEC-8K-2026-05-11].

2026-12-31catalystHealthcare and aerospace product cycle can drive core-growth recoveryHigh impact

Management tied the recovery to a refreshed product portfolio and said early traction in denture systems and high-performance metal printing should support sustained long-term growth, while the FY2025 release highlighted a target of 20% aerospace and defense growth in 2026; if these end markets keep compounding, core revenue can outgrow the legacy base [#SEC-8K-2026-05-11] [#SEC-8K-2026-03-09].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology